Metformin-induced cholestatic hepatitis

Fadel E. Nammour, Nabil F. Fayad, Steven R. Peikin

Research output: Contribution to journalArticle

41 Scopus citations


Objective: To report a case of metformin-induced cholestatic hepatitis. Methods:We present a detailed case report, including laboratory and biopsy findings. In addition, similar cases from the literature are reviewed. Results: In a 68-year-old man with newly diagnosed diabetes mellitus, metformin therapy was begun. The dosage initially was 500 mg twice daily and later was increased to 850 mg twice a day. Four weeks after metformin treatment was initiated, jaundice, pruritus, and liver enzyme abnormalities were noted. The patient underwent an extensive work-up, including a hepatitis screen, ultrasonography, magnetic resonance imaging, and endoscopic retrograde cholangiopancreatography, all of which showed normal findings. A liver biopsy revealed severe cholestasis and mild portal inflammation. Treatment with metformin was discontinued, and the liver enzymes normalized except for a persistently increased level of alkaline phosphatase, most likely related to a prolonged cholestatic effect of metformin. Conclusion: Although rare, metformin can be responsible for inducing liver damage, and patients and physicians should be aware of this side effect.

Original languageEnglish (US)
Pages (from-to)307-309
Number of pages3
JournalEndocrine Practice
Issue number4
StatePublished - Jul 1 2003


ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Nammour, F. E., Fayad, N. F., & Peikin, S. R. (2003). Metformin-induced cholestatic hepatitis. Endocrine Practice, 9(4), 307-309.